

# Cloning, Sequencing, Expression, and Insertional Inactivation of the Gene for the Large Subunit of the Coenzyme B<sub>12</sub>-dependent Isobutyryl-CoA Mutase from *Streptomyces cinnamonensis*\*

(Received for publication, September 16, 1997, and in revised form, December 19, 1997)

Katja Zerbe-Burkhardt‡, Ananda Ratnatilleke‡, Nathalie Philippon‡, Ashley Birch‡, Andreas Leiser‡, Jan W. Vrijbloed‡, Daniel Hess§, Peter Hunziker§, and John A. Robinson‡¶

From the Institutes of ‡Organic Chemistry and §Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland

Purification of the coenzyme B<sub>12</sub>-dependent isobutyryl-CoA mutase (ICM) from *Streptomyces cinnamonensis* gave a protein of ~65 kDa by SDS-polyacrylamide gel electrophoresis, whose gene *icmA* was cloned using sequences derived from tryptic peptide fragments. The gene encodes a protein of 566 residues (62,487 Da), with 43–44% sequence identity to the large subunit of methylmalonyl-CoA mutase (MCM) from *S. cinnamonensis* and *Propionibacterium shermanii*. Targeted disruption of the *icmA* gene yielded an *S. cinnamonensis* mutant devoid of ICM activity. The *IcmA* protein is ~160 residues shorter than the large subunit of the bacterial MCMs, corresponding to a loss of the entire C-terminal coenzyme B<sub>12</sub> binding domain. The sequence of the (β/α)<sub>8</sub>-barrel comprising residues A1–A400 in *P. shermanii* MCM is highly conserved in *IcmA*. The protein was produced in *Streptomyces lividans* and *Escherichia coli* with an N-terminal His<sub>6</sub> tag (His<sub>6</sub>-*IcmA*), but after purification His<sub>6</sub>-*IcmA* showed no ICM activity. In the presence of coenzyme B<sub>12</sub>, protein from *S. lividans* and *S. cinnamonensis* of ~17 kDa by SDS-polyacrylamide gel electrophoresis could be selectively eluted with His<sub>6</sub>-*IcmA* from a Ni<sup>2+</sup> affinity column. After purification, this small subunit showed no ICM activity but gave active enzyme when recombined with coenzyme B<sub>12</sub> and *IcmA* or His<sub>6</sub>-*IcmA*.

Several polyketide antibiotic-producing streptomycetes have been shown to promote the interconversion of *n*- and isobutyrate. The best studied example is *Streptomyces cinnamonensis*, the producer of the commercially important polyether antibiotic monensin A (1). The interconversion of *n*- and isobutyrate occurs *in vivo* at the level of CoA<sup>1</sup> thioesters, as

shown using a GC assay for ICM (EC 5.4.99.13) activity in cell-free extracts of *S. cinnamonensis* (2); the free acids are not substrates for the mutase. At the same time, ICM from *S. cinnamonensis* was shown to catalyze the interconversion of isobutyryl- and *n*-butyrylcarba(dethia)-CoA analogues (Fig. 1). These analogues are stable toward hydrolysis, thereby facilitating estimation of the equilibrium constant for this rearrangement, which was found to be ≈1.3 in favor of isobutyrylcarba(dethia)-CoA. The reaction catalyzed by ICM is very similar to that of the well known and widely distributed MCM (3). In both reactions, a COSCoA group migrates to an adjacent methyl, and a hydrogen atom is transferred in the reverse direction predominantly with retention of configuration (1, 4, 5).

The MCM from *S. cinnamonensis* has been cloned and sequenced (6). It was shown to be closely related in primary structure to the MCM from *Propionibacterium shermanii* (7), comprising a heterodimer with subunits of ≈65 and ≈79 kDa. The human and mouse MCMs are both homodimers with a subunit size of ≈75 kDa (8–10). Like the *P. shermanii* MCM, the *S. cinnamonensis* MCM does not catalyze the interconversion of *n*- and isobutyryl-CoA at a detectable rate (2, 6).

The structure determination of the cobalamin-binding domain of methionine synthase, a member of the methyl transferase family, revealed for the first time a protein-bound form of methylcobalamin, a vitamin B<sub>12</sub> derivative (11). The cobalamin was shown bound to the protein with a histidine residue providing an axial imidazole ligand to Co<sup>3+</sup>, replacing the dimethylbenzimidazole appended to the corrin ring. Stupperich *et al.* (12) had shown earlier that protein-bound cobamides can have a histidine ligand. This key histidine residue in methionine synthase is found in a motif DXHXXG, which is conserved in some (but not all) of the coenzyme B<sub>12</sub>-dependent mutases (13). A similar coordination of coenzyme B<sub>12</sub> by histidine was also implicated in coenzyme B<sub>12</sub> bound to MCM (14).

More recently, the crystal structure of the heterodimeric MCM from *P. shermanii* was reported (15). This revealed an active site, inaccessible to solvent, that is embedded along the axis of a (β/α)<sub>8</sub>-barrel domain in the large subunit. Coenzyme B<sub>12</sub> is sandwiched on one end of the β/α-barrel, between this and a C-terminal domain with a fold similar to those of flavodoxin and the cobalamin-binding domain of methylcobalamin-dependent methionine synthase (11). Apart from illuminating many important aspects of substrate and coenzyme binding to MCM, this structure also confirmed the coordination of cobalt by the histidine in the conserved DXHXXG motif within the C-terminal flavodoxin-like, coenzyme B<sub>12</sub> binding domain.

We report here our efforts to purify ICM from *S. cinna*-

\* This work was supported by grants from the Swiss National Science Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBank™/EBI Data Bank with accession number(s) U67612.

¶ To whom correspondence should be addressed: Institute of Organic Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. Tel.: 41-1635-4242; Fax: 41-1635-6812; E-mail: robinson@oci.unizh.ch.

<sup>1</sup> The abbreviations used are: CoA, coenzyme A; aa, amino acid(s); GC, gas chromatography; Hm, hygromycin (<sup>R/S</sup>, resistant/sensitive); *hygB*, hygromycin B phosphotransferase gene, confers Hm<sup>R</sup>; ICM, butanoyl-CoA:2-methylpropanoyl-CoA mutase; *icmA*, gene encoding the large subunit of ICM; *IcmB*, the small subunit of ICM; IPTG, isopropyl-β-D-thiogalactopyranoside; MCM, methylmalonyl-CoA mutase; nt, nucleotide(s); orf(s), open reading frame(s); Polk, Klenow large fragment of *E. coli* DNA polymerase I; PAGE, polyacrylamide gel electrophoresis;

Ts, thiostrepton (<sup>R/S</sup>, resistant/sensitive); PCR, polymerase chain reaction; bp, base pair(s); kb, kilobase pair(s).




FIG. 1. The reactions catalyzed by MCM and ICM.

*monensis*, which have led to the cloning and sequencing of a gene encoding its large subunit, denoted here *icmA*. This gene was used to produce a recombinant protein in *Streptomyces lividans* and *Escherichia coli* with a His<sub>6</sub> tag fused to the N terminus. We also show that this recombinant protein can be used to isolate an additional small subunit of the enzyme present in *S. lividans* and *S. cinnamomensis*. This work has also allowed a comparison of the primary sequences of ICM and MCM large subunits, with unexpected implications regarding the mode of coenzyme B<sub>12</sub> binding to ICM.

#### EXPERIMENTAL PROCEDURES

##### Assays

The assay used for ICM is essentially that described previously (6). Protein concentration was determined by Bradford assay (16).

##### Fermentation

*S. cinnamomensis* A3823.5 (a high yield monensin-producing strain kindly made available by Lilly (17)) was grown in 15-liter batch fermentations using a procedure described earlier (18). Cell paste (500–600 g per fermentation) could be stored at  $-70^{\circ}\text{C}$  over several weeks without substantial loss of ICM activity.

##### Enzyme Isolation

**Buffers**—Buffers were prepared as follows: buffer A, potassium phosphate (50 mM, pH 7.4) with EDTA (5 mM), dithiothreitol (1 mM),  $\beta$ -mercaptoethanol (0.05% v/v), and glycerol (5% v/v); buffer B, same as buffer A with phenylmethylsulfonyl fluoride (1 mM), benzamidine (1 mM), glycerol (total 20% v/v), and activated charcoal (20 g/liter); buffer C, same as buffer A with KCl (1.0 M); buffer D, same as buffer A with KCl (0.1 M) and Tris-HCl (0.1 M); buffer E, same as buffer A but with 20% glycerol; buffer F, Tris-HCl (250 mM, pH 8.3), glycine (1.92 M); buffer G, Tris-HCl (100 mM, pH 8.2), NaCl (1.0 M), CaCl<sub>2</sub> (2.0 mM), and MeCN (10%); buffer H, same as buffer A with Tris-HCl (0.15 M); buffer I, sodium acetate (0.1 M, pH 4) and NaCl (0.5 M); buffer J, Tris-HCl (100 mM, pH 8) and NaCl (0.5 M); buffer K, potassium phosphate (50 mM, pH 7.4), KCl (300 mM), glycerol (5% v/v), imidazole (20 mM),  $\beta$ -mercaptoethanol (0.05% v/v), benzamidine (1 mM), and phenylmethylsulfonyl fluoride (1 mM); buffer L, same as buffer K except imidazole (300 mM); buffer M, potassium phosphate (50 mM, pH 7.4),  $\beta$ -mercaptoethanol (0.05% v/v), dithiothreitol (1 mM); buffer N, potassium phosphate (50 mM, pH 7.4), KCl (150 mM).

**Affinity Chromatography**—A vitamin B<sub>12</sub> affinity column (19, 20) was prepared as follows. Vitamin B<sub>12</sub> (130 mg) in aqueous HCl (0.5 M, 46 ml) was stirred at  $37^{\circ}\text{C}$  for 3 h. The solution was neutralized with aqueous NH<sub>3</sub> and applied to a column of Alumina N (2  $\times$  36 cm, ICN, Germany). After eluting unchanged vitamin B<sub>12</sub>, partially hydrolyzed cobalamins were eluted with aqueous NH<sub>3</sub> (0.2 M). After lyophilization, these were applied in water to Q-Sepharose (1.6  $\times$  20 cm, Pharmacia Biotech Inc.), and monocarboxylic acids were separated from di- and tricarboxylic acids by elution with a gradient from 0.2 M triethylamine, pH 11, to 0.2 M triethylamine, 0.5 M acetic acid, pH 1. TLC on cellulose plates (eluting with *sec*-butyl alcohol/acetic acid/water (127:1:50)) was used to monitor this separation ( $R_f$  (B<sub>12</sub>) = 0.5,  $R_f$  (monocarboxylic acids) = 0.6). Fast atom bombardment-mass spectrometry of the monocarboxylic acid fraction gave  $m/z$  = 1356.3 (M<sup>+</sup>). The monocarboxylic acids (16 mg) were then coupled over 16 h to EAH-Sepharose (5 ml, Pharmacia) using *N*-ethyl,*N'*-(3-dimethylaminoisopropyl)carbodiimide




FIG. 2. Coomassie Blue-stained SDS-PAGE gel of protein obtained after the purification of ICM from *S. cinnamomensis* (see Table I): lane A, after DEAE; lane B, after Superdex; lane C, after preparative gel electrophoresis; lane D, after vitamin B<sub>12</sub> affinity chromatography. Positions of molecular mass standards are shown.

and protocols recommended by the manufacturer (Pharmacia). The gel was then washed with water, with buffer I, then buffer J, and finally with water.

**Cell Disruption and Ammonium Sulfate Fractionation**—Ultrasonic disruption of cell paste ( $\approx 500$  g) in buffer B (750 ml) was carried out over 15 min at  $4$ – $10^{\circ}\text{C}$ , and then solids were removed by centrifugation ( $27,500 \times g$  for 45 min). Ammonium sulfate was added to the supernatant to 35% saturation at  $4^{\circ}\text{C}$  and pH 7.5. After centrifugation ( $47,800 \times g$ , 1 h) and filtration through glass wool, ammonium sulfate was added to 75% saturation. Centrifugation ( $47,800 \times g$  for 1 h) afforded a protein pellet (Table I), which could be stored at  $-80^{\circ}\text{C}$  over several months.

**Chromatography on DEAE-Sepharose**—Protein from above ( $\approx 5$  g wet weight) was applied to DEAE-Sepharose (2.6  $\times$  45 cm, Pharmacia) equilibrated with buffer A and eluted with a gradient (0–100% buffer C) over 500 ml at a flow rate of 3 ml/min. ICM appeared in the eluate at  $\approx 92$ –100% buffer C. The active fractions containing  $\approx 300$  mg of protein were concentrated by ultrafiltration (Centriprep-10, Amicon).

**Q-Sepharose**—Protein from the foregoing step (in 3 batches, total  $\approx 1.0$  g) was applied to a column of Q-Sepharose (2.6  $\times$  15 cm, Pharmacia) pre-equilibrated with buffer A and eluted with a gradient (0–50% buffer C) over 540 ml at a flow rate of 4 ml/min. ICM eluted at  $\approx 34$ –42% buffer C, whereas MCM eluted at  $\approx 47$ –50% buffer C. The fractions containing ICM were concentrated by ultrafiltration (Centricon-10, Amicon).

**Gel Filtration**—The active protein from the preceding step (6  $\times$  20-mg batches) was applied to a Hiloal 16/60 Superdex-200 column ( $\approx 120$ -ml bed volume, Pharmacia) pre-equilibrated with buffer D and eluted (0.3 ml/min) with buffer D. ICM eluted at  $\approx 69$ –75 ml.

**Preparative Gel Electrophoresis**—Continuous preparative native gel electrophoresis was performed with a model 491 Prep-Cell (Bio-Rad). Protein from the preceding step (20 mg) was applied in buffer E (3 ml) to a gel comprising a stacking layer (5.25% acrylamide) followed by the fractionating gel (8% acrylamide). Electrophoresis (at 40 mA) was performed using buffer F as running buffer at  $4^{\circ}\text{C}$ . Proteins eluted from the gel were diverted to a fraction collector.

**Affinity Chromatography**—Protein from the previous step (2.5 mg) was applied to affinity resin (1 ml, see above) in buffer A. The column was then eluted with a KCl gradient (10–100% buffer C). ICM appeared from the column at  $\approx 0.2$  M KCl. This fraction showed a major protein band on SDS-PAGE (Fig. 2), with apparent mass of  $\approx 65$  kDa and several minor components of lower mass.

##### Peptide Sequencing

The ICM-containing protein from above ( $\approx 200$   $\mu\text{g}$ ) was electrophoresed by SDS-PAGE (12%, 10  $\times$  10-cm gel), electroblotted onto a cationic polyvinylidene difluoride membrane (Immobilon CD, Millipore), and visualized by negative staining (Quickstain, Zelon Research). The membrane spot containing the adsorbed protein (of  $\approx 65$  kDa) was cut out and incubated in buffer G (10  $\mu\text{l}$ ) with trypsin (0.3  $\mu\text{g}$ , Promega) for 15 h at  $37^{\circ}\text{C}$ . Free peptides were washed from the membrane with 10% aqueous trifluoroacetic acid (1  $\mu\text{l}$ ) and 10% aqueous MeCN with 0.1% trifluoroacetic acid (10  $\mu\text{l}$ ). The peptides were analyzed by microbore high pressure liquid chromatography (C<sub>8</sub> column, 300  $\approx$  pore size, 1  $\times$  250 mm, Vydac) eluting with a gradient of 2–80% v/v MeCN in water,



<--	L R Q	I A E	S L L	Q Y R D	A H Y	E A P	T C G D	V I H	P I A	D P E L
1	TTAGGCGCTG	GATCGCTCG	GAGAGCAGCT	GGTAACGGTC	CGCGTGGTAC	TCGCGCGGGG	TGACGCGCTC	CACGATGTGC	GGGATCGCGT	CGGGCTCGAG
	I V L	A P A	D G I A	D A F	T D V	W S F Y	A E A	S A A	G S A	H Q G
101	GATCACCAAG	GCGGGGCGGT	CGCCGATCGC	GTCCGCGAAC	GTGTCTCACCC	AGCTTCGGTA	GGCCTTCGCA	CTGGCGCGCG	CGCCCGCGGA	GTGCTGACCA
	C D R	H P I N	Y A V	L V A	T R D E	K V A	G R T A	A K A V	D P A	P D D
201	CAGTCCGGGT	CGGGGATGTT	GTACGCGACG	AGTACGGCGG	TGCGGTCTCTC	CTTGACCGCG	CCCCCGCTCG	CCCTTCGCGA	GTCGCGCGCC	GGATCGTCCC
	G A P W	V A M A	R E A	S I R R	L T E A	A D E A	A R G Q	E E W	Q R V	Q R A A
301	CGGCGCGGCA	CACGGCCATG	GCCCGTTCGG	AGATGGCCCT	GAGCGTCTCG	CGGTCTCTCG	CGCGGCCCTG	TTCTCTCCAC	TGCGTGCACCT	GCGCGCGA
	P S D	P D V	W F T G	A P P	G A S	A T A P	K R V	A A E	E K T G	D S G
401	GGGGCTGTGC	GGGTGACCC	GGCGGGTGC	GGCGGGGGG	CGGCGCTCG	CGGTGGCGGG	CTTGCGCACG	GCCGCTCTCT	CCTTCGTGCT	GTCGACCC
	P D S	S S C G	A P L	G L A	A L A A	L A T	F T R	L L R H	M	orf 4
501	GGGTCTGAGG	AGGAGCAGCC	TGCCGGGAGC	CCGAGGGCGG	CGAGGGCGCG	GAGTGGCGTG	AACGTGCGGA	GCAGCCGGTG	CCGAGCGGGA	CCTTGGCGGA
	TGGTGACAGT	GACGGTCACT	CAGCCCGGCA	ATCGTTACAT	AAAGGACTAT	TCAAGCTCTT	GTGCCACACC	GCCTCCGGTG	CCGAGCGGCA	ACCCGCGCGA
701	CACCAAGAGC	CCCGCCCGCG	CGCGGAGCCG	TACGTACGAC	CGAATTGCGA	GACGGGGCTG	ACCACCATAT	GACCGCGGGG	TAAGGTGCGA	GCCCGTCCGA
									orf 3 ->	V P K
801	AGCCGCTCAG	CTCCCTCTTC	GATCCCATCG	CCCGCGCCGA	CGAGCTCTGG	AAGCAGCGCT	GGGGATCGGT	CCCGGCCATG	GGCGGCATCA	CCTCGATCAT
	P L S	L P F	D P I A	R A D	E L W	K Q R W	G S V	P A M	G A I T	S I M
901	GCGGGCGCAC	CAGATCTCTG	TCGCGGAGGT	CGACGCGGTC	CTTCAAGCGT	ACGGAAGTAC	CTTTCGCGCG	TACGAGGCGC	TGGTGTCTCT	CACCTTCTCT
	R A H	Q I L L	A E V	D A V	V K P Y	G L T	F A R	Y E A L	V L L T	T F S
1001	CAGGCGCGCG	AGTTCGCGAT	GTCAAGAGTG	GGCGAGCGGC	TCATGTGTGA	CCCGACCTCG	GTCACGAACA	CCGTGTGACG	CCTGTGAAG	TCCGCGCTGG
	Q A G E	L P M	S K I	G E R L	M V H	P T S	V T N T	V D R	L V K	S G L V
1101	TCGACGAAGC	CCGAACCC	AACAGCGGCC	CGCGACGCT	CGCTCCATC	ACGGAAGAAG	CGTGCAGAGT	CGTGCAGGCG	GCCACCGCGC	AGCTGATGCG
	D K R	P N P	N D G R	G T L	A S I	T E K G	R E V	V E A	A T R E	L M A
1201	GATGCTGATC	GGGTCTCGGG	TGTACGACGC	GGAGAGGTGC	GGGAGATCT	TCCGGAATGT	GCGGCCCTTG	CGGTGTGCGG	CGCGCGATT	CGAGGAGCAG
	M D F	G L G V	Y D A	E E C	G E I F	A M L	R P L	R V A A	R D F	E E Q
1301	TAGGCGCCGC	CGGTGAGAA	GTGGGATCGG	GTCGTCCCGG	TACGGCGGG	GGCGCGAAG	ATCGCGTGAA	AAGGGCGGTT	ACGCTCGTAG	CCATGAACG
									orf 2 ->	M K R
1401	ACGCGTCTCG	ACCCGCTACC	GGGTGATGCG	TACGTCTACC	CGCGTCTATG	TCCTCATCTCT	GTGCGCTGCG	ATGGTGGCCA	AGTACGCGTT	CGACAAGGGC
	S V L	T R Y R	V M A	Y V T	A V M L	L I L	C A C	M V A K	Y G F	D K G
1501	GAGGCTCTGA	CTCTCTCTCG	GTCGCAAGTG	CACGGCGTGC	TCATACATAT	CTACCTGATC	TTCCGCTTTC	ACCTGGGCTC	CAAGGCGAAG	TGGCGGCTTC
	E G L T	L V V	S Q V	H G V L	Y I I	Y L I	F A F D	L G S	K A K	W P F G
1601	GCAAGCTGCT	CTGGGTCTGT	GTCTCGGGCA	GCGTCCGAC	CGCGCCCTTC	TCGTCTGAGC	CCGTGACGTC	CCGTGACGTC	GCCGCGTGA	TCCGCGGCGG
	K L L	W V L	V S G T	I P T	A A F	F V E R	K V A	R D V	E P L I	A D G
1701	CTCCCGGCTC	ACCGGAAGG	CGTAACCCGC	ACCGCCACGG	ACAGGTCCTG	GGCGGTTGCG	CATCGACTTT	TACTAGGACG	TCCTAGTAAA	TTGATGGA
	S P V	T A K A	*						orf1 icm ->	M
1801	TGAGCGCTGA	CGGATCGAG	GAGGCGCGCC	GAGCGTGCCA	GGCGCGTTAC	GACAAGGCCC	GCAAGCGCGA	TCTGCGACTTC	ACCGAGCTCT	CGCGGCGGCC
	D A D	A I E	E G R R	R W Q	A R V	D K A R	K R D	A D F	T T L S	G D P
1901	CGTCCGACCC	GTCTCGCGCC	CCCGGCGCCG	GGACACGTAC	GACGGCTTCG	AGCGGATTCG	CTGGCGCGGG	GAGTACCCCT	TCACCGCGCG	GCTCTCTACC
	V D P	G V G G P	R P G	D T Y	D G F E	R I G	W P G	E Y P F	T R G	L Y A
2001	ACCGGCTACC	GGGCGCGCAC	CTGGACCATC	CGCCAGTTTC	CGCGGCTTCG	CAACGCGGAG	CAGACGAACG	AGCGCTACAA	GATGATCTG	GCCAACCGCG
	T G V Y	G R T	W T I	R Q F A	G F G	N A E	Q T N E	R Y K	M I L	A N G G
2101	CGCGCGCGCT	CTCCGCTCGC	TTGACATGCG	CGACCTCAT	GGGCGCGAC	TCCGACGACC	CGCGCTCGCT	CGCGGAGGTC	GGCCATCTGC	GTGTCGCCAT
	G G L	S V A	F D M P	T L M	G R D	S D D P	R S L	G E V	G H C G	V A I
2201	ATGTACCTCG	GCCGACATGG	AGGTCTCTCT	CAAGGACATC	CCGCTCGGCG	ACGTGACGAC	GTCCATGACC	ATCAGCGGCG	CCGCGGCTGC	CGTCTCTTGC
	D S A	A D M E	V L F	K D I	P L G D	V T T	S M T	I S G P	A V P	V F C
2301	ATGTACCTCG	TGCGCGCGCA	GCGCGACGGC	GTCGACCCCG	CGGTCTCGCA	CGGACGCTCG	CAGACCGACA	TCCTCAAGGA	GTACATCGCC	CAGAAGAGT
	M Y L V	A A E	R O G	V D P A	V L N	G T L	Q T D I	F K E	Y I A	Q K E W
2401	GGCTCTTCCA	GCCCGAGCG	CACCTCGGCC	TCATCGCGCA	CTGTATGGAG	CACGTGCGCG	GCGACATCCC	CGCGTACAAG	CCGCTCTCGG	TCCTCGGCTA
	L F O	P E P	H L R L	I G D	L M E	H C A R	D I P	A Y K	P L S V	S G Y
2501	CCACATCTCG	GAGGCGCGGG	CGACGCGCGC	GCAGGAGCTC	GCCTACACCC	TCGCGGACGG	CTTTCGGGTAC	GTGGAATCGG	GCCTCTCGCG	CGGCGTGCAC
	H I R	E A G A	T A A	Q E L	A Y T L	A D G	F G Y	V E L G	L S R	G L D
2601	GTGGAGCTCT	TCGCGCGCGG	CCTCTCTCTC	TCCTTCGACG	CGCAGCTGCA	CTTCTTCGAG	GAGATCGCGA	AGTTTCGCGC	CGCAGCGCGC	ATCTGGGCGC
	V D V F	A P G	L S F	F F D A	H V D	F F E	E I A K	F R A	A R R	I W A R
2701	CGTGGCTCTG	GGACGAGTAC	GGAGCGAAGG	ACAGTGGGCT	CGCTTCCACA	CGCAGACCGC	GGGGGTCTCG	CTCAGCGCCC	CTCAGCGCCC	AGCAGCGGTA
	W L R	D E Y	G A K T	E K A	Q W L	R F H T	O T A	G V S	L T A O	O P Y
2801	CAACAACGCT	GTGCGGACGG	CGGTGGAGGG	CCTCGCGCGC	GTGCTCGGCG	GCACGAATCT	CCTGCAACAC	AACGCTCTCG	ACGAGACCTT	TGCCCTCCCC
	N N V	V R T A	V E A	L A A	L G G	T N S	L H T	N A L D	E T L	A L P
2901	AGCGAGCAGG	CCCGCGGAGT	CGCGCTCGCG	ACCCAGCAGG	TGCTGATGGA	GGAGACCGCG	GTCCGCAACG	TCGCGGACCC	GCTGGGCGCG	TCCTGGTACA
	S E Q A	A E I	A L R	T Q Q V	L M E	E T G	V A N V	A D P	L G G	S W Y I
3001	TCGAGCAGCT	CACCGACGCG	ATCAGGCGCG	ACGCGGAGAA	GATCTTCTGAG	CAGATACAGG	AGCGGGGCGG	CGCGGCTCGC	CCCGACGGGC	AGCACCCTGAT
	E Q L	T D R	I E A D	A E K	I F E	Q I R E	R R G R	R A C	P D Q G	H P I
3101	CGGGCGGATC	ACCTTCGCGA	TCCTGCGCGG	CATCGAGGAC	GGCTGGTTCA	CCGCGGAGAT	CGCGGAGTCC	GCCTTCCAGT	ACCAGCGGTC	CCTGGAGGAG
	G P I	T S G I	L R G	I E D	G W F T	G E I	A E S	A F Q Y	Q R S	L E K
3201	GGCGACAAGC	GGTTCGTCGG	CGTCAACTGC	CTCGAAGGCT	CGGTCACCGG	CGACCTGGAG	ATCTCTGCGC	TCAGCCACGA	GGTGCAGCGC	GAGCAGGTGC
	G D K R	V V G	V N C	L E G S	V T G	D L E	I L R V	S H E	V E R	E Q V R
3301	GGGAGCTTGC	GGGGCGCAAG	GGGCGGCGTG	ACGATGCGCG	GGTGGGGGCG	TCGCTGCGAC	CGATGCTCGC	CGCTGCGCGG	GACGGGTCTG	ACATGATGTC
	E L A	G R K	G R R D	D A R	V R A	S L D A	M L A	A A R	D G S N	M I A
3401	CCCCATCTGT	GAGGCGGTCG	GACCCCTCGG	GACCTCTGGG	GAGATCTGCG	GGGTGCTTTC	CGATGATGGG	GGGGTCTACG	TGGAGCGCGC	CGGGTCTTGA
	P M L	E A V R	A E A	T L G	E I C G	V L R	D E W	G V Y V	E P P	G F *
3501	GGGCGCGGTC	CTTTTTCGCT	CGGCTCTGCT	GTGGCTGGTC	CGCGAGTTTC	CCGACCCCTT	GAAAGACCCC	GGCGCTTTTC	CTTCTGGCTC	CGCCTCTGTC
	TGCTCTGCGG	GGCGGCTGGG	GCTGTCTGCG	CAGTCTCCCG	CGCCCCCTGC	CGCACCTTGC	CCCCCGCGCG	TGCATGCGCG	CCCCACCTGT	ACGGGGGCTG
3601	CTGGGCGGCA	CGCTGACGGG	TGCGGTCTGG	GCGTGGCGGG	GTCTTTTAGG	GGCGGCGGGA	ACTGCGCGAG	CAACCCCGAC	CCACCGCGAG	GTGACGCGG
	AGCGGCGGAC	CGCCCGGAGA	CGGGGGCAAA	ACGGGCGGAG	TGCCCCCGCG	CGCGGCGGCG	CGCGAATTCG	TAGGTTTAA	GGGCGGCGGT	CAGGCGCGGT
3801	CGCGAGCGCG	TCACACGCCC	CGGTCCCGAG	AGACCCCGTG	ACCTGACGCG	GCCACGCGCG	CACCGCGCGG	ATCGCCGATG	GAGCGCGGAT	CGCCACCGTC
				orf 5 ->	V					
4001	CTCGGCGCGC	TGCTGCTCGG	CGGCTCTCGG	GAGGTGAGTG	CGAGCCCGCG	GCCCGACGCC	AAGGTCCAGG	ACGACTTCTG	CTCCCTGATG	CCCGAGGTGC
	L G A	L V G	G S G	E V S A	S P P	P E P	K V Q D	D F D	S L G	P E V R
4101	GCGCCGCGAA	GCTCTCCGAC	GGGCGGACGG	CCCACTACTC	GGACACGGGC	GACAAGGAGC	GCAAGCGGCG	CCGTGTTTATC	GGCGGACACG	GCACGAGCGC
	A A K	L S D	G R T A	H Y S	D T G	D K D G	K P A	L F I	G T G	T S A
4201	CCGCGCTCTC	CACATGACCG	ACTTCTTCCG	CTCAGCGCGC	GAGGACCTGG	GCCTTCCGCT	CATCTCCGTG	GAGCGCAACG	GCTTGTGCGA	CACCGGCTTC
	R A S	H M T D	F F R	S T R	E A D G	L R L	I S V	E R N G	F G D	T A F
4301	GACGAGAAGC	TGCGACACCG	CGACTTCGCG	AAGGACGCCC	TCGAGTCTCT	CGACCGGCTC	GG			
	D E K L	G T A	D F A	K D A L	E V L	D R L	-->			

FIG. 4. The nt sequence of the cloned DNA from *S. cinnamomensis*. The location of orfs predicted from a FRAME analysis are shown. The *orf4* is encoded on the opposite strand (not shown), and the predicted aa sequence is shown above the nt sequence. The other orfs are encoded on the DNA strand shown, and the aa sequence is given below. The aa sequences of seven IcmA tryptic peptides, and the N-terminal sequence, determined by protein sequencing are given in *italics* and are *underlined*. The predicted start codons (determined for *orf1*) are shown in *bold*. An inverted repeat between *orf1* and *orf2* is *underlined*. The nt sequences at the 5' and 3' ends of *icmA* corresponding to the target sites of PCR primers KB3 and KB4 are also *underlined*.

was applied in portions to Ni<sup>2+</sup>-NTA resin (3 × 1.5 cm, Pharmacia) and washed with buffer K, and His<sub>6</sub>-IcmA was eluted with buffer L and then dialyzed against buffer M. Chromatography on MonoQ with buffer M and a gradient of 0–100% KCl (1 M) afforded His<sub>6</sub>-IcmA (30 mg) which was homogeneous by SDS-PAGE (Fig. 7).

Plasmid pOCI633 was introduced into *S. lividans* 1362 (25). After growth in YEME (5 liters) with kanamycin (5 µg/ml) at 30 °C to an A<sub>600</sub> of 0.7–1.0, the cultures were induced with Ts (5 µg/ml). After a further 12–15 h the cells were collected and sonicated in buffer K; cell debris was removed by centrifugation, and His<sub>6</sub>-IcmA was purified as above (yield 16 mg).

#### Purification of IcmB from *S. lividans*

*S. lividans* 1362[pOCI633] was grown in YEME (5 liters) and induced with Ts, as described above. The cells were sonicated in buffer K;

cell debris was removed; coenzyme B<sub>12</sub> (10 µM) was added, and the protein (~1.6 g) was chromatographed in portions on Ni<sup>2+</sup>-NTA resin (3 × 1.5 cm) in the dark. The resin was washed with buffer K containing coenzyme B<sub>12</sub> (10 µM), before eluting with buffer L and dialyzing against buffer M (yield 24 mg). The sample was applied to MonoQ with buffer M containing coenzyme B<sub>12</sub> (10 µM), washed with buffer M (no coenzyme B<sub>12</sub>), and eluted with a gradient of 0–100% KCl (1 M) to give a fraction containing mainly His<sub>6</sub>-IcmA (16 mg, eluting at 270 mM KCl), followed by a pink colored protein (2.5 mg, eluting at 370 mM KCl) with high ICM activity and a UV spectrum with an absorption maximum at 525 nm. The pink colored protein was dialyzed against buffer M, applied to MonoQ, and eluted in buffer M with a gradient of 0–100% KCl (1 M). The small subunit IcmB (~4 µg) eluted as a sharp peak at 200 mM KCl and was homogeneous by SDS-PAGE (see Fig. 7).

Purification of IcmB from *S. cinnamomensis*

*S. cinnamomensis* was grown for 3–4 days at 30 °C in YEME (5 liters) supplemented with valine (6.6 g/liter). The cells were collected and sonicated in buffer K, and cell debris was removed by centrifugation (yield 1.8 g of protein). To this was added recombinant His<sub>6</sub>-IcmA (29 mg), prepared as described above, and coenzyme B<sub>12</sub> (10 μM). The protein was chromatographed in portions on Ni<sup>2+</sup>-NTA resin (3 × 1.5 cm) in the dark. The resin was washed with buffer K containing coenzyme B<sub>12</sub> (10 μM), before eluting with buffer L and dialyzing against buffer M (yield 22 mg). The sample was chromatographed on MonoQ, as described above for IcmB from *S. lividans*. The protein fraction eluting at ~300 mM KCl (15 mg) contained mainly His<sub>6</sub>-IcmA, whereas fractions containing the holoenzyme (4.5 mg) eluted at ~350 mM KCl and were dialyzed against buffer M. The protein was then applied to a gel filtration column (Superose 12, Pharmacia) and eluted at a flow rate of 0.2 ml/min with buffer N. A peak containing IcmB (~2 μg) eluted with an apparent mass of ~16–18 kDa (Fig. 7). This protein showed no ICM activity until both IcmA and coenzyme B<sub>12</sub> were added (Fig. 8).

## RESULTS

**Enzyme Assay**—The ICM assay involves hydrolyzing CoA thioesters at the end of the reaction, extraction of *n*- and isobutyric acids into ethyl acetate, and quantification by GC. Typical GC chromatograms from assays performed with recombinant ICM (see above) are shown in Fig. 8. To aid in the quantification of isobutyrate formed, a known amount of valeric acid was added to each assay as an internal standard.

**Enzyme Purification and Peptide Sequencing**—The ICM was

TABLE I  
Purification of ICM from extracts of *S. cinnamomensis*

Purification step	Protein <sup>a</sup> mg	Isobutyrate <sup>b</sup> μM	<i>n</i> -Butyrate/ isobutyrate <sup>c</sup>	Activity <sup>d</sup> μmol/min/mg protein
1. [NH <sub>4</sub> ] <sub>2</sub> SO <sub>4</sub>	ND			
2. DEAE	800	31	6.4:1	2.6 × 10 <sup>-4</sup>
3. Q-Sepharose	120	36	4.4:1	1.5 × 10 <sup>-3</sup>
4. Superdex	20	45	4.2:1	7.5 × 10 <sup>-3</sup>
5. Gel electrophoresis	2.5	53	4.3:1	8.9 × 10 <sup>-3</sup>
6. B <sub>12</sub> affinity chromatography	0.26	80	2.6:1	2.3 × 10 <sup>-2</sup>

<sup>a</sup> Amount of protein available following each step, starting from ~500 g (wet weight) cell paste.

<sup>b</sup> The concentration of isobutyrate attained at the end of the assay is calculated by comparison to the amount of *n*-valeric acid in the EtOAc extract. In each assay, *n*-butyryl-CoA (250 μM) in buffer (200 μl) and coenzyme B<sub>12</sub> were incubated with protein for 30 min at 30 °C (see "Experimental Procedures").

<sup>c</sup> The ratio of *n*- to isobutyrate peak volumes detected by GC is shown. This indicates how far the interconversion has proceeded in each assay. No correction for hydrolysis of substrates during the course of the assay is included.

<sup>d</sup> Activity indicates amount of isobutyrate formed (see Footnote b) in μmol/min/mg protein.

purified as outlined in Table I. The MCM and ICM activities were separated by Q-Sepharose ion-exchange chromatography, with ICM eluting in the middle and MCM at the end of the salt gradient. The protein finally obtained was shown by SDS-PAGE to contain a major component with apparent mass ~65 kDa, together with several minor components of lower mass (Fig. 2). Attempts to further purify the ~65-kDa protein led to large losses in ICM activity. The ~65-kDa protein was isolated by SDS-PAGE and subjected to N-terminal amino acid sequence analysis (see Fig. 4). The ~65-kDa protein was also digested with trypsin, and the resulting peptides were analyzed by high pressure liquid chromatography and electrospray-mass spectrometry. The masses of tryptic fragments were compared with the MOWSE peptide mass fingerprint data base (33), but no similar entries were found. Several tryptic fragments were sequenced by Edman degradation (Fig. 4), revealing up to 75% sequence identity to segments of the MCM large subunit from *S. cinnamomensis* (6) and *P. shermanii* (7).

**Gene Cloning and Sequencing**—Two tryptic peptide sequences were used to design oligonucleotides for PCR. The PCR afforded a ~310-bp DNA fragment, which was found to be 70% identical in DNA sequence and 55% in translated protein sequence to the MCM large subunit from *S. cinnamomensis*. This PCR product was used as a probe to isolate hybridizing clones from a genomic DNA library prepared in λEMBL4. From one clone, the region encoding the putative *icmA* gene was isolated and sequenced on both strands by the dideoxy method (see Figs. 3 and 4).

**Sequence Analysis**—The 4362-bp DNA segment sequenced showed a total G/C content of 71%. A frame analysis (Fig. 5) was performed using CODONPREFERENCE in the GCG software (The Genetics Computer Group, Madison, WI, version 8.1-UNIX (34)). This revealed three complete orfs (*orf1*, *orf2*, and *orf3* in Figs. 3 and 4), each with a G/C content of ~75, ~50, and ~95% at the first, second, and third positions of each codon, respectively, which is highly characteristic of protein coding regions in *Streptomyces* DNA (35). Downstream of the presumptive stop codon of *orf1*, the G/C distribution changes (Fig. 5), strongly suggesting that the stop codon has been correctly identified. Two incomplete orfs (*orf4* and *orf5*) were also predicted, extending outward from each end of the region sequenced. The incomplete *orf4* (nt 1–583) shared over the available protein sequence a similarity of ~32% to endoglucanases in the EMBL/SWISSPROT data base. Comparisons of *orf2* (nt 1393–1725), -3 (nt 794–1303), and -5 (nt 3938–4326) with the data base failed to identify proteins with significant sequence similarities, so their functions are presently uncertain. The *orf1* was identified as the putative *icmA* gene due to its high sequence similarity, at the DNA and protein levels, to the large

FIG. 5. FRAME analysis performed using CODONPREFERENCE in the GCG software (34) (PrefWindow: 25, Rare codon Threshold: 0.1, BiasWindow: 25, density: 143.1). The analysis shows the percentage G/C versus A/T at the third position of each codon for all possible reading frames. The location of orfs 1–5 deduced in this way (see text) is shown below each trace.




TABLE II  
Protein sequence identities and similarities between IcmA and the large (MutB) and small (MutA) subunits of MCM from *S. cinnamomensis* and *P. shermanii*, and the human and mouse MCMs (using BESTFIT, in the GCG software)

Protein sequence	Identity	Similarity
	%	%
MCM <i>S. cinnamomensis</i> MutA	29.6	51.5
MCM <i>S. cinnamomensis</i> MutB	44.0	63.7
MCM <i>P. shermanii</i> MutA	26.1	51.1
MCM <i>P. shermanii</i> MutB	42.9	65.3
MCM mouse	40.4	63.7
MCM human	42.3	64.3

subunits of *S. cinnamomensis* and *P. shermanii* MCM, as well as to the human and mouse MCMs (Table II). The 3'-untranslated region downstream of *orf1* shows no homology at the nt or aa levels to MCMs, again consistent with the correct identification of the stop codon of *orf1*.

The N-terminal amino acid sequence determined for IcmA agrees with that predicted by the DNA sequence, starting at nt 1800 with an ATG codon. Termination occurs at nt 3500 with a TGA codon, corresponding to a protein with 566 aa, and a mass of 62,487 Da, which agrees well with the mass of ~65 kDa estimated by SDS-PAGE. The peptide sequences determined from tryptic fragments are encoded at the expected locations in the *icmA* gene sequence (Fig. 4). A comparison of the IcmA protein sequence, with those of the homodimeric and heterodimeric MCM large subunits from various organisms, was performed with PILEUP in the GCG software (Fig. 9). A DOT-PLOT comparison between ICM and the MCM large subunit from *P. shermanii* is shown in Fig. 10.

**Disruption of the *S. cinnamomensis icmA* Gene**—A targeted insertional inactivation of the *icmA* gene in *S. cinnamomensis* was achieved by first inserting a cassette containing a functional Hm resistance gene (*hygB*) into the unique *SacI* site within the cloned *S. cinnamomensis icmA* gene (Figs. 3 and 6). The *icmA* containing *hygB* was cloned into the vector pGM160 (29) to give plasmid pOCI643 which, however, could not be introduced into *S. cinnamomensis*, possibly due to instability of the plasmid under the growth conditions. Subsequently, by removing the entire *E. coli* sequences from pOCI643, and introducing a plasmid denaturation step (30), *S. cinnamomensis* Ts<sup>R</sup> Hm<sup>R</sup> transformants were isolated, which after further growth at 39 °C yielded Ts<sup>S</sup> Hm<sup>R</sup> colonies. A Southern blot hybridization analysis of genomic DNA isolated from one of these clones confirmed that the *icmA* gene had been inactivated, consistent with a double crossover event (Fig. 6). Extracts of the *S. cinnamomensis icmA::hygB* mutant were devoid of ICM activity.

**Expression of the *icmA* Gene**—The *icmA* gene was amplified by PCR using oligonucleotide primers incorporating *NdeI* and *BamHI* sites, such that the *NdeI* site incorporates an ATG start codon. The PCR product was cloned after digestion with *NdeI* and *BamHI* between the *NdeI/BamHI* sites in pET3a to afford pOCI614. After introduction into *E. coli* BL21(DE3)pLysS and induction with IPTG at 30 °C, large amounts of soluble protein were isolated, with the correct apparent mass on SDS-PAGE, and the correct N-terminal amino acid sequence. This protein, however, was devoid of ICM activity.

To produce IcmA in *S. lividans* 1326, the gene was cloned on the *NdeI/BamHI* fragment into the high copy number expression vector pIJ4123 to afford pOCI633. Only a very low ICM activity was found in cell extracts of *S. lividans* 1326[pIJ4123] grown in YEME. However, cell extracts from *S. lividans* 1326[pOCI633] after induction with Ts showed high levels of ICM activity, typically about 5–10 × higher than seen in ex-




FIG. 6. A, the genomic region of wild type (*wt*) *S. cinnamomensis* encoding IcmA, as deduced from the sequenced DNA (see Figs. 3 and 4). The restriction sites (*BglI*, *BglII*, *SalI*, and *SacI*) and their positions found within the 4362 bp sequenced are indicated. Below is a map showing the expected organization of orfs, and positions of restriction sites, after a double crossover from the *hygB*-containing *icmA* gene in the vector and selection for Ts<sup>S</sup> and Hm<sup>R</sup>. B, hybridization analysis of a Southern blot of DNA from the Ts<sup>S</sup> Hm<sup>R</sup> transformant (denoted *ko*) and the wild type strain, digested with *BglI*, *BglII*, or *SalI*. The probe was the PCR fragment amplified by primers KB3 and KB4 (see "Experimental Procedures") and digested with *NdeI/BamHI*. This probe includes the entire *orf1*. The positions of size markers are shown to the left.

tracts of *S. cinnamomensis*. The His<sub>6</sub>-IcmA was purified to homogeneity by Ni<sup>2+</sup>-chelate affinity and gel filtration chromatography but showed no mutase activity (Fig. 8). The same His<sub>6</sub>-IcmA was also produced in *E. coli* using the vector pET14b (Novagen) but again showed no ICM activity.

**Purification of an ICM Small Subunit**—Cell extracts from *S. lividans* 1326[pOCI633] were fractionated by metal-chelate affinity chromatography in the presence of coenzyme B<sub>12</sub>, to recover His<sub>6</sub>-IcmA and its associated subunit. Subsequent ion-exchange chromatography on MonoQ (Pharmacia) in the absence of coenzyme B<sub>12</sub> gave a protein similar to 17 kDa by SDS-PAGE (Fig. 7), which by itself was devoid of ICM activity, but gave highly active ICM after incubation with His<sub>6</sub>-IcmA (or IcmA) and coenzyme B<sub>12</sub>. The intact holoenzyme showed a UV-visible absorption spectrum with a maximum at 525 nm typical of protein-bound adenosyl cobalamin (data not shown).




FIG. 7. Above is shown a Coomassie Blue-stained SDS-PAGE (8–25% gradient) gel of purified His<sub>6</sub>-IcmA from *E. coli* (lane A) and IcmB isolated from *S. lividans* (lane B). Below is shown a Coomassie Blue-stained SDS-PAGE (20% homogeneous) gel with purified His<sub>6</sub>-IcmA (lane A) and IcmB isolated from *S. cinnamonensis* (lane B). The positions of size markers are indicated.

The His<sub>6</sub>-IcmA alone showed no UV-visible absorption maximum at 525 nm and does not bind coenzyme B<sub>12</sub> under these conditions.

The ICM small subunit was isolated from wild type *S. cinnamonensis*, and from the *icmA::hygB* mutant (see above), in a similar way by addition of His<sub>6</sub>-IcmA to cell extracts, followed by metal-chelate affinity chromatography in the presence of coenzyme B<sub>12</sub>, ion-exchange chromatography on MonoQ, and gel filtration. The yield of the small subunit was lower, but SDS-PAGE again revealed a protein of ~17 kDa (Fig. 7), which by itself was inactive but yielded highly active ICM upon incubation with both coenzyme B<sub>12</sub> and His<sub>6</sub>-IcmA (Table III and Fig. 8), and afforded a holoenzyme with a UV-visible maximum at 525 nm.

#### DISCUSSION

Crucial to any enzyme purification is an assay that allows detection and quantification of catalytic activity. The assay for ICM used here is sensitive but ill-suited for accurate quantification of specific activity, especially when limited amounts of protein are available. For a typical assay during the purification of ICM, sufficient protein (~50–200 µg) was taken to afford between a ~10:1 to 2:1 ratio (as determined by GC) of *n*-to isobutyrate in a single 30-min incubation at 30 °C, with *n*-butyryl-CoA as substrate. The amount of isobutyrate formed per min per mg of protein was then estimated, based on this single time point in the reaction. This gives an estimate of the mutase activity at each stage of the purification (Table I) but clearly does not correspond to the specific activity of the enzyme.

The enzyme is present in low amounts in cell extracts of *S. cinnamonensis* but is stable at room temperature over several hours. A variety of chromatographic methods failed to yield a significant improvement in purity without incurring major losses of ICM activity. With hindsight, it seems likely that

TABLE III

Estimations of ICM activity reconstituted by mixing recombinant His<sub>6</sub>-IcmA (produced in *E. coli*) with IcmB isolated from *S. cinnamonensis* (see Fig. 7) in the presence of coenzyme B<sub>12</sub> (20 µM)

Without added coenzyme B<sub>12</sub> the enzyme is completely inactive. The protein concentrations were determined by the Bradford assay, assuming a mass of 17 kDa for IcmB. The total amount of each subunit added to each assay in picomoles is shown. The substrate was *n*-butyryl-CoA (280 µM) in potassium phosphate buffer (50 mM, pH 7.4) with EDTA (5 mM) and glycerol (5% v/v), at 30 °C. The *i/n* ratio gives the ratio of *iso*-to *n*-butyrate determined by GC after 30 min incubation (compare Fig. 8), from which the amount of isobutyryl-CoA formed and hence the enzyme activity were determined (see "Discussion"). Compare with Table I.

Assay	IcmA	IcmB	<i>i/n</i> ratio	Activity
	pmol	pmol		µmol/min/mg
1	2.5	5	0.12	1.0
2	2.5	10	0.09	0.78
3	5	10	0.22	0.85
4	5	2.5	0.10	0.82
5	10	2.5	0.13	1.04
6	10	5	0.29	1.05




FIG. 8. Gas chromatograms from assays of ICM activity performed with purified His<sub>6</sub>-IcmA (~1 µg) and small subunit from *S. cinnamonensis* (~0.1 µg) with added coenzyme B<sub>12</sub> (A); only the small subunit (~0.1 µg) with added coenzyme B<sub>12</sub> (B); both proteins as in A, but without added coenzyme B<sub>12</sub> (C). Only in A is the formation of isobutyrate (*i*) from *n*-butyrate (*n*) apparent. The valeric acid added as a standard prior to extraction of the *n* and isobutyrate is denoted by V. The IcmA protein alone shows no activity and gives assay results exactly comparable to those shown in B and C.

these losses were due to the separation of subunits of the enzyme. This was not anticipated, since we had succeeded in purifying the heterodimeric MCM from *S. cinnamonensis* without major difficulties.<sup>2</sup> However, a significant gain in ICM purity was achieved by incorporating vitamin B<sub>12</sub> affinity chromatography late in the purification scheme (Table I).

After six purification steps the ICM contained a major component with apparent mass ~65 kDa on SDS-PAGE, along with several proteins of lower mass (Fig. 2). No protein of

<sup>2</sup> A. Leiser, unpublished work.



human	MLRAKQLFLSPPHYLRQVKESSGRLIQORLLHQQLPLHPWAALAKQLKGNPEDLIWHTPEGISIKPLYSKRD..TMDLPE..ELPGVKPFTRGPY	96
mouse	MLRAKQLFLSPPHYLRQVKESSGRLIQORLLHQQLPLHPWAALAKQLKGNPEDLIWHTPEGISIKPLYSRAD..TMDLPE..ELPGVKPFTRGPY	94
pgin	.....MKPNYKIDIKSAGFVAKDAIRWAEKGIADWRTPEQIMVKPLTKDDLEGMHLD..YVSGLPPLTRGPY	70
psherm	.....MSTLPRFSDVLGNAPVPADAARRFEELAAKAGTGEAWETAQIPVGTLFNEDVYKMDWLD..TYAGIPFVHGPY	75
scinna	.....MRIPEFDIILGAGGGPSGSAEGRWAARAVKESVGSKESDILWETPEGIATVPLKPLTGADVEGLDFLE..TYGPAVPLRGPY	78
icm	.....MDADAIEEGRRRWQARYDKARKRDADFTLTSGDPVDPVYGRPGDTYDGFERIGWFGPEYPTGRGLY	66
human	PTMYTFRPWTIRQYAGFSTVEESNKFYKDNIKAGQQLSVAFLDATHRGVYSDNPRVRGVDVGMAGVAIDTVEDTKILFDGIPLEKMSVSMTMNGAVIPVL	196
mouse	PTMYTFRPWTIRQYAGFSTVEESNKFYKDNIKAGQQLSVAFLDATHRGVYSDNPRVRGVDVGMAGVAIDTVEDTKILFDGIPLEKMSVSMTMNGAVIPVL	194
pgin	SGMYPMRPWTIRQYAGFSTAEESNAFYRRNLASQQLSVAFLDATHRGVYSDNPRVRGVDVGMAGVICSLEDKMLVFDGIPLSKMSVSMTMNGAVILPIL	170
psherm	ATMYAFRPWTIRQYAGFSTAEESNAFYRRNLAAQQLSVAFLDATHRGVYSDNPRVRGVDVGMAGVAIDSIYDMRELFDGIPLDQMSVSMTMNGAVILPIL	175
scinna	PTMYVNPWTIRQYAGFSTAEESNAFYRRNLAAQQLSVAFLDATHRGVYSDNPRVRGVDVGMAGVAIDSIYDMRELFDGIPLDQMSVSMTMNGAVILPVL	178
icm	ATGVRGRITWTIRQYAGFSTAEESNAFYRRNLAAQQLSVAFLDATHRGVYSDNPRVRGVDVGMAGVAIDSIYDMRELFDGIPLDQMSVSMTMNGAVILPVL	166
human	ANFIVTGEQGVPEKLTGTIQTNDILKEFMVRNTYIFPPDPMSKIADIFEYTAHMKPKFNSISISGYHMQEAGADALEAYTLADGLEYSRTGLQAGL	296
mouse	ATFIVTGEQGVPEKLTGTIQTNDILKEFMVRNTYIFPPDPMSKIADIFEYTAHMKPKFNSISISGYHMQEAGADALEAYTLADGLEYSRTGLQAGL	294
pgin	AFYINAGLEQAGKLEEMAGTIQTNDILKEFMVRNTYIYPPFESMRIADIFEYTSQNMKPKFNSISISGYHMQEAGADALEAYTLADGLEYSRTGLQAGL	270
psherm	ALYVTAEEQGVPEKLTGTIQTNDILKEFMVRNTYIYPPFESMRIADIFEYTSQNMKPKFNSISISGYHMQEAGADALEAYTLADGLEYSRTGLQAGL	275
scinna	ALYVTAEEQGVPEKLTGTIQTNDILKEFMVRNTYIYPPFESMRIADIFEYTSQNMKPKFNSISISGYHMQEAGADALEAYTLADGLEYSRTGLQAGL	278
icm	CMYLVAERQGVDPVAVLNLQTDIFKEYIAQKWLFPQEPHLRLIGDLMHCARDIPAYKPLSVSGYHIREAGATAQELAYTLADGLEYSRTGLQAGL	266
human	TIDEFAPRLSFFWGIQGNFYMEIAKMRAGRRLWAHLIEKMFQPKNSKSLLLRAHCQTSQWSLTQEDPYNNIVRTAIEAMAAYFGGTQSLHNSFDEALGL	396
mouse	TIDEFAPRLSFFWGIQGNFYMEIAKMRAGRRLWAHLIEKMFQPKNSKSLLLRAHCQTSQWSLTQEDPYNNIVRTAIEAMAAYFGGTQSLHNSFDEALGL	394
pgin	DVDAFAPRLSFFWGIQGNFYMEIAKMRAGRRLWAHLIEKMFQPKNSKSLLLRAHCQTSQWSLTQEDPYNNIVRTAIEAMAAYFGGTQSLHNSFDEALGL	369
psherm	NVDQFAPRLSFFWGIQGNFYMEIAKMRAGRRLWAHLIEKMFQPKNSKSLLLRAHCQTSQWSLTQEDPYNNIVRTAIEAMAAYFGGTQSLHNSFDEALGL	374
scinna	DVDAFAPRLSFFWGIQGNFYMEIAKMRAGRRLWAHLIEKMFQPKNSKSLLLRAHCQTSQWSLTQEDPYNNIVRTAIEAMAAYFGGTQSLHNSFDEALGL	377
icm	DVDVAFAPRLSFFWGIQGNFYMEIAKMRAGRRLWAHLIEKMFQPKNSKSLLLRAHCQTSQWSLTQEDPYNNIVRTAIEAMAAYFGGTQSLHNSFDEALGL	366
human	PTVKSARIARNTQIIQEEESGIPKVPADPWGGSYMECLTNDVDAALKLINEIEEMG.....GMAKAVAEGIPKLRIEECAAARQARID	480
mouse	PTVKSARIARNTQIIQEEESGIPKVPADPWGGSYMECLTNDVDAALKLINEIEEMG.....GMAKAVAEGIPKLRIEECAAARQARID	478
pgin	PTDFSARIARNTQIIQEEETLVCKEIDPWGGSYVESLTNVLHKAATLIEVEEMG.....GMAKAIETGLPKLRIEECAAARQARID	453
psherm	PTDFSARIARNTQIIQEEETLVCKEIDPWGGSYVESLTNVLHKAATLIEVEEMG.....GMAKAIETGLPKLRIEECAAARQARID	458
scinna	PTDFSARIARNTQIIQEEETLVCKEIDPWGGSYVESLTNVLHKAATLIEVEEMG.....GMAKAIETGLPKLRIEECAAARQARID	461
icm	PSEQAEIARLTQOVLMEETGVANVADPLGGSWYIEQLTDRIEADAEKIFPEQIRERGRACPDGQHPGIPITSGILRGIEDGFTGEIAESAYQORSLD	466
human	SGSEVIVGVNKHLEKEDSVHLLAIDIIISLRKKQIEKLKIKSSRQALAEHLCAALTECAASG....DGNILALAVDASRARCITVGEITDAFKKVFGE	575
mouse	SGSEVIVGVNKHLEKEDSVHLLAIDIIISLRKKQIEKLKIKSSRQALAEHLCAALTECAASG....DGNILALAVDASRARCITVGEITDAFKKVFGE	573
pgin	SHQQVIVGVNKHLEKEDSVHLLAIDIIISLRKKQIEKLKIKSSRQALAEHLCAALTECAASG....EGNLLDLAVKAAGRLASGLSIDACEKVVFR	548
psherm	SGRQPLIGVGNKYLKELKEDSVHLLAIDIIISLRKKQIEKLKIKSSRQALAEHLCAALTECAASG....EGNLLDLAVKAAGRLASGLSIDACEKVVFR	558
scinna	SGRQPLIGVGNKYLKELKEDSVHLLAIDIIISLRKKQIEKLKIKSSRQALAEHLCAALTECAASG....EGNLLDLAVKAAGRLASGLSIDACEKVVFR	561
icm	KDGRQVIVGVNKHLEKEDSVHLLAIDIIISLRKKQIEKLKIKSSRQALAEHLCAALTECAASG....EGNLLDLAVKAAGRLASGLSIDACEKVVFR	559
human	HKANDRMVSGAYRQYEGESKEITSAIKRVHFKFMEREGRRRLILVAKMGQDGHDRGAKVIATGFDLGFVDVIGPLFQTPREVAQVADADVHVGVSSTA	675
mouse	HKANDRMVSGAYRQYEGESKEITSAIKRVHFKFMEREGRRRLILVAKMGQDGHDRGAKVIATGFDLGFVDVIGPLFQTPREVAQVADADVHVGVSSTA	673
pgin	YKAVIRITISGVYSSEGEDKDFAHAKELAEKFAKKEGRQPRIMIAKMGQDGHDRGAKVIATGFDLGFVDVIGPLFQTPREVAQVADADVHVGVSSTA	648
psherm	YTAQIRITISGVYSSEGEDKDFAHAKELAEKFAKKEGRQPRIMIAKMGQDGHDRGAKVIATGFDLGFVDVIGPLFQTPREVAQVADADVHVGVSSTA	658
scinna	HAGQIRITISGVYSSEGEDKDFAHAKELAEKFAKKEGRQPRIMIAKMGQDGHDRGAKVIATGFDLGFVDVIGPLFQTPREVAQVADADVHVGVSSTA	661
icm	YVEPPGF*.....	566
human	AGHKTIVPELILKELNSLGRPDILVMCGGVIPQDYEFLEFVGVSNNVFGPGTRI PKAAVQVLLDDIEKCLEKKQSV*	750
mouse	AGHKTIVPELILKELNSLGRPDILVMCGGVIPQDYEFLEFVGVSNNVFGPGTRI PKAAVQVLLDDIEKCLEKKQSV*	748
pgin	AGHKTIVPELILKELNSLGRPDILVMCGGVIPQDYEFLEFVGVSNNVFGPGTRI PKAAVQVLLDDIEKCLEKKQSV*	715
psherm	GGHLLIVPALRELKELKELNSLGRPDILVMCGGVIPQDYEFLEFVGVSNNVFGPGTRI PKAAVQVLLDDIEKCLEKKQSV*	728
scinna	AGHLLIVPALRELKELKELNSLGRPDILVMCGGVIPQDYEFLEFVGVSNNVFGPGTRI PKAAVQVLLDDIEKCLEKKQSV*	733
icm	.....	

Fig. 9. A PILEUP comparison of the aa sequences of (in descending order) the human and mouse MCMs, the large subunits of MCM from *Porphyromonas gingivalis*, *P. shermanii*, and *S. cinnamomensis*, and the ICM large subunit IcmA from *S. cinnamomensis*. Residues that are conserved in all six sequences are indicated under the sequences by \*. The DXHXXG motif is indicated by ●●● (see text).

higher mass was apparent by SDS-PAGE. Tryptic peptide fragments isolated from the  $\approx 65$ -kDa protein showed high sequence identities (25–75%) to portions of the large subunits of MCM from both *S. cinnamomensis* (6) and *P. shermanii* (7), consistent with this being a subunit of a closely related enzyme.

A PCR-based reverse genetic approach then allowed the cloning and sequencing of the *icmA* gene (denoted *orf1* in Fig. 3). The translated sequence of 566 aa ( $M_r$  62,487) shows a high similarity across almost its entire length to the large subunit of MCM from microbial sources (Fig. 10), as well as to the homodimeric human and mouse MCMs (Table II). It is noteworthy that an *orf* similar in size and sequence to that of the small subunit of MCMs from *S. cinnamomensis* and *P. shermanii* was not found directly adjacent to this *icmA* gene (Fig. 3). In contrast, the *orfs* for the large and small subunits of *S. cinnamomensis* and *P. shermanii* MCM possess overlapping stop and start codons, a device which is thought to lead to translational coupling and hence to the production of stoichiometric amounts of the two polypeptides.

Proof that *orf1* is necessary for ICM activity was obtained by disruption of the gene in *S. cinnamomensis*. By targeted insertional inactivation, the chromosomal *icmA* gene was replaced in a double crossover with a copy containing a functional Hm resistance gene inserted into its unique *SacI* site (Fig. 6), using the vector pGM160. This vector contains a temperature-sensitive *Streptomyces* origin of replication, resulting in its loss from host cells grown at the non-permissive temperature of 39 °C

(29). The vector has been used previously for gene disruptions in *S. cinnamomensis* (36, 37). The resulting *S. cinnamomensis icmA::hygB* mutant was devoid of ICM activity under the usual assay conditions, providing direct evidence for a functional role of *icmA* in ICM activity. This mutant will be of value to study the influence of ICM on polyketide antibiotic production in this strain, since the enzyme has been implicated in an important biochemical pathway, furnishing methylmalonyl-CoA from isobutyryl-CoA and *n*-butyryl-CoA (1).

A catalytic function for the IcmA protein was sought by expression in a heterologous host. In a first attempt, the protein was made in the cytoplasm of *E. coli*, by placing the *icmA* gene under the transcriptional control of a T7 RNA polymerase promoter in the plasmid pET3a (31). Although large amounts of soluble IcmA could be made in this way, it was devoid of ICM activity. The reason for the lack of mutase activity became clear after IcmA had been produced in *S. lividans*.

A second attempt to produce IcmA was made using a high copy number expression vector (pIJ4123) suitable for *Streptomyces* spp. (32). The vector contains the thiostrepton-inducible promoter and ribosome-binding site of the *tipA* gene. Immediately downstream is a translational start codon (ATG) followed by a sequence encoding a 20-residue N-terminal peptide including a His<sub>6</sub> tag and a thrombin recognition sequence, followed by a unique *NdeI* site allowing fusion of the peptide leader to the protein of interest. After subcloning the *icmA* gene into this vector, and introduction into *S. lividans* 1326, substantially






FIG. 10. A DOTPLOT comparison of the MCM large subunit from *P. shermanii* and the IcmA from *S. cinnamonensis* (using COMPARE in the GCG software (34), window 30, stringency 15.0).

higher ICM activity was detected in cell-free extracts than seen in *S. lividans* 1326 with pIJ4123. The His<sub>6</sub>-IcmA was readily purified by Ni<sup>2+</sup>-chelate affinity chromatography and gel filtration but then showed no ICM activity. Another protein fraction was detected, however, eluting from the gel filtration column after His<sub>6</sub>-IcmA, which showed high ICM activity. This fraction contained several proteins in the size range 12–50 kDa, as well as small residual amounts of His<sub>6</sub>-IcmA. As expected, the activity was dependent upon added coenzyme B<sub>12</sub>. This suggested that at least one additional smaller subunit is necessary to complement the IcmA large subunit and afford active mutase *in vitro*. Indeed, it is notable that active mutase can be reconstituted with His<sub>6</sub>-IcmA derived from *S. cinnamonensis* and small subunit(s) endogenous to the wild type *S. lividans* in which the large subunit had been produced.

The ICM small subunit was purified from *S. lividans* and subsequently also from *S. cinnamonensis*, by relying on its association with His<sub>6</sub>-IcmA in the presence of coenzyme B<sub>12</sub>, and exploiting the convenient His<sub>6</sub>-affinity handle. The combination of metal-chelate affinity chromatography in the presence of coenzyme B<sub>12</sub>, and subsequent ion-exchange and/or gel filtration chromatography in the absence of the coenzyme, gave a protein of about 17 kDa by SDS-PAGE (Fig. 7), which was inactive alone but afforded highly active ICM after addition of His<sub>6</sub>-IcmA (or IcmA) and coenzyme B<sub>12</sub> (Fig. 8). The activity of the reconstituted mutase was estimated to be approximately 1.0 μmol/min/mg, as shown in Table III. However, we note again here that the assay, as described above, is not well suited for determining specific activities. Nevertheless, this value can be compared with the activity determined for ICM isolated from *S. cinnamonensis*, as outlined in Table I. From this comparison it is clear that the mutase reconstituted from recombinant His<sub>6</sub>-IcmA and IcmB from *S. cinnamonensis* (Table III and Fig. 7) has a higher activity than that found for the wild type enzyme at the end of the purification (Table I and Fig. 2).

A comparison of the IcmA protein sequence with those of the human and mouse MCMs and the large subunits from *P. gingivalis*, *S. cinnamonensis*, and *P. shermanii* MCMs performed using PILEUP in the GCG software (34) is shown in Fig. 9. A DOTPLOT comparison of IcmA and the MCM large subunit from *P. shermanii* is shown in Fig. 10. The DOTPLOT comparison reveals that the region of highest sequence similarity extends approximately over residues 60–400 in both proteins. The sequence identity in this region is about 50%. The most

striking difference, however, is the significant truncation of IcmA in comparison to all MCMs (Fig. 9), corresponding to the loss of the C-terminal ≈160 amino acid residues from MCM. A second significant difference is a 16-residue insertion in IcmA (residues 424–439), which is absent in all the MCM sequences reported to date.

The crystal structure of the *P. shermanii* MCM reported recently (15) revealed an N-terminal (β/α)<sub>8</sub>-barrel domain in the large subunit, from residues A1–A400. The high sequence identity (≈50%) of this region to residues 1–392 in IcmA suggests that the (β/α)<sub>8</sub>-barrel is conserved in the structure of IcmA. Residues A401–A559 in the *P. shermanii* MCM correspond to a largely helical linker, which connects the (β/α)<sub>8</sub>-barrel with the C-terminal, so-called coenzyme B<sub>12</sub> binding, flavodoxin-like domain (A560–A728). The linker residues A401–A559 in this MCM correspond in the sequence comparison to residues 393–560 in IcmA (Fig. 9), although the sequence identity is only ≈18% in this region (Fig. 10). But after just 6 more residues IcmA terminates.

A striking aspect of the recently determined crystal structures of MCM is the replacement of the dimethylbenzimidazole group of coenzyme B<sub>12</sub> as an axial Co<sup>3+</sup> ligand by the imidazole of a histidine situated in the C-terminal coenzyme B<sub>12</sub> binding domain of the large subunit. This imidazole is linked through a hydrogen-bonded network to the side chains of two other residues forming a ligand triad (38), which in MCM is His<sup>610</sup>-Asp<sup>608</sup>-Lys<sup>604</sup>. The nucleotide tail of the cofactor fills a cavity in this domain, which places the dimethylbenzimidazole group in a tight hydrophobic pocket. These intimate interactions between coenzyme B<sub>12</sub> and protein suggest a key role for this domain in modulating the reactivity of MCM.

In the case of ICM, the large subunit contains no contiguous coenzyme B<sub>12</sub> binding domain but requires a separate small subunit (IcmB) of ≈17 kDa to bind coenzyme B<sub>12</sub> and afford active mutase. This indicates that the IcmB small subunit has assumed the role of a coenzyme B<sub>12</sub> binding domain in ICM and will most likely be homologous to the corresponding region of the MCM large subunit. In support of this conclusion, preliminary results from ongoing work have shown that the IcmB from *S. lividans* and *S. cinnamonensis* have N-terminal protein sequences that are about 70% identical to the coenzyme B<sub>12</sub> binding domain in MCM (data not shown). In addition, a thorough sequence comparison has shown that the IcmB N-terminal protein sequence is not encoded in the genomic DNA shown in Fig. 4. Presently, we must conclude that the *icmB* gene is not encoded by one of the small orfs found adjacent to *icmA* in this work. Future work will focus on cloning *icmB* from *S. cinnamonensis*, the quaternary structure of the holoenzyme, and the determination of the kinetic and thermodynamic parameters of this mutase reaction.

**Acknowledgments**—We thank Dr. Mervyn Bibb for providing pIJ4123, Prof. Wohlleben for pGM160, and Annelies Meier for expert technical assistance.

#### REFERENCES

1. Reynolds, K. A., O'Hagan, D., Gani, D., and Robinson, J. A. (1988) *J. Chem. Soc. Perkin Trans. I* 3195–3207.
2. Brendelberger, G., Rétey, J., Ashworth, D. M., Reynolds, K., Willenbrock, F., and Robinson, J. A. (1988) *Angew. Chem. Int. Ed. Engl.* **27**, 1089–1090.
3. Rétey, J. (1982) in *B12* (Dolphin, D., ed) Vol. 2, pp. 357–379, John Wiley & Sons, Inc., New York.
4. Rétey, J., and Robinson, J. A. (1982) *Stereospecificity in Organic Chemistry and Enzymology*, Vol. 13, pp. 185–207, Verlag Chemie, Weinheim, Germany.
5. Moore, B. S., Eisenberg, R., Weber, C., Bridges, A., Nanz, D., and Robinson, J. A. (1995) *J. Am. Chem. Soc.* **117**, 11285–11291.
6. Birch, A., Leiser, A., and Robinson, J. A. (1993) *J. Bacteriol.* **175**, 3511–3519.
7. Marsh, E. N., McKie, N., Davis, N. K., and Leadlay, P. F. (1989) *Biochem. J.* **260**, 345–352.
8. Ledley, F. D., Lumetta, M., Nguyen, P. N., Kolhouse, J. F., and Allen, R. A.

- (1988) *Proc. Natl. Acad. Sci. U. S. A.* **85**, 3518–3521
9. Jansen, R., Kalousek, F., Fenton, W., Rosenberg, L. E., and Ledley, F. D. (1989) *Genomics* **4**, 198–205
  10. Wilkemeyer, M. F., Crane, A. M., and Ledley, F. D. (1990) *Biochem. J.* **271**, 449–455
  11. Drennan, C. L., Huang, S., Drummond, J. T., Matthews, R. G., and Ludwig, M. L. (1994) *Science* **266**, 1669–1674
  12. Stupperich, E., Eisinger, H. J., and Albracht, S. P. J. (1990) *Eur. J. Biochem.* **193**, 105–109
  13. Marsh, E. N. G., and Holloway, D. E. (1992) *FEBS Lett.* **310**, 167–170
  14. Padmakumar, R., Taoka, S., Padmakumar, R., and Banerjee, R. (1995) *J. Am. Chem. Soc.* **117**, 7033–7034
  15. Mancia, F., Keep, N. H., Nakagawa, A., Leadlay, P. F., McSweeney, S., Rasmussen, B., Bösecke, P., Diat, O., and Evans, P. R. (1996) *Structure* **4**, 339–350
  16. Bradford, M. M. (1976) *Anal. Biochem.* **72**, 248–254
  17. Stark, W. M., Knox, N. G., and Westhead, J. E. (1968) *Antimicrob. Agents Chemother.* **1967**, 353–358
  18. Priestley, N. D., and Robinson, J. A. (1989) *Biochem. J.* **261**, 853–861
  19. Allen, R. H., and Majerus, P. W. (1972) *J. Biol. Chem.* **247**, 7695–7701
  20. Yamada, R.-H., and Hogenkamp, H. P. C. (1972) *J. Biol. Chem.* **247**, 6266–6270
  21. Yanisch-Perron, C., Vieira, J., and Messing, J. (1985) *Gene (Amst.)* **33**, 103–109
  22. Agarwal, R. K., and Perl, A. (1993) *Nucleic Acids Res.* **21**, 5283–5284
  23. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1994) *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc., New York
  24. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  25. Hopwood, D. A., Bibb, M. J., Chater, K. F., Kieser, T., Bruton, C. J., Kieser, H. M., Lydiate, D. J., Smith, C. P., Ward, J. M., and Schrempf, H. (1985) *Genetic Manipulation of Streptomyces: A Laboratory Manual*, The John Innes Foundation, Norwich
  26. Frischauf, A. M., Lehrach, H., Poutska, A., and Murray, N. (1982) *J. Mol. Biol.* **170**, 827–842
  27. Sanger, F., Nicklen, S., and Coulson, A. (1977) *Proc. Natl. Acad. Sci. U. S. A.* **74**, 5463–5467
  28. Lydiate, D. J., Ashby, A. M., Henderson, D. J., Kieser, H. M., and Hopwood, D. A. (1989) *J. Gen. Microbiol.* **135**, 941–955
  29. Muth, G., Nussbaumer, B., Wohlleben, W., and Pühler, A. (1989) *Mol. Gen. Genet.* **219**, 341–348
  30. Oh, S. H., and Chater, K. F. (1997) *J. Bacteriol.* **179**, 122–127
  31. Studier, F. W., Rosenberg, A. H., Dunn, J. J., and Dubendorff, J. W. (1990) *Methods Enzymol.* **185**, 60–89
  32. Takano, E., White, J., Thompson, C. J., and Bibb, M. J. (1995) *Gene (Amst.)* **166**, 133–137
  33. Pappin, D. J. C., Hojrup, P., and Bleasby, A. J. (1993) *Curr. Biol.* **3**, 327–332
  34. Devereux, J., Haeberli, P., and Smithies, O. (1984) *Nucleic Acids Res.* **12**, 387–395
  35. Bibb, M. J., Findlay, P. R., and Johnson, M. W. (1984) *Gene (Amst.)* **30**, 157–166
  36. Arrowsmith, T. J., Malpartida, F., Sherman, D. H., Birch, A., Hopwood, D. A., and Robinson, J. A. (1992) *Mol. Gen. Genet.* **234**, 254–264
  37. Leiser, A., Birch, A., and Robinson, J. A. (1996) *Gene (Amst.)* **177**, 217–222
  38. Ludwig, M. L., Drennan, C. L., and Matthews, R. G. (1996) *Structure* **4**, 505–512